An observational study in Breast Cancer, sponsored by Institut Claudius Regaud. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-31.
Sponsored by Institut Claudius Regaud · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Breast Neoplasms by Institut Claudius Regaud — 6 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut Claudius Regaud.
Among the 26 studies in Breast Neoplasms by Institut Claudius Regaud, this one is one of 2 that started in 2015, is one of 3 observational ones, and was the 10th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →6 of the 26 studies in Breast Neoplasms by Institut Claudius Regaud are open now, in 1 country. Recruiting first, the newest first:
Institut Claudius Regaud · Sites in France
Ages 66+ · Men only
Institut Claudius Regaud · Sites in France
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18 mo+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 120 across the 23 interventional studies, 205 across the 3 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 32 are open to participants now.
2 of the studies in Breast Neoplasms by Institut Claudius Regaud that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05378204Institut Claudius RegaudStudy Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. | 2027-01 |
| NCT07558343Institut Claudius RegaudMale breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2 | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Breast Neoplasms by Institut Claudius Regaud, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In order to accelerate border crossing between basic research and clinical research in breast cancer, it is necessary to easily use clinical and biological data. That is the reason why it is very important to create a clinical, biological and pathologic beast cancer database, mainly prospective but also retrospective. All data are from patients treated in Toulouse Centre.
The scientific community will easily have access to clinical and biological informations through a centralized, structured database , leading to optimize patients with breast cancer treatment.
Female patient with breast cancer of any stage
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Database of patients with breast cancer
Time frame: 10 years
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Feb 2015, a primary completion of Jan 2025 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.